CAR-T Therapy Beyond B-Cell Hematological Malignancies

被引:0
|
作者
Canichella, Martina [1 ]
de Fabritiis, Paolo [1 ,2 ]
机构
[1] ASL Roma2, St Eugenio Hosp, Hematol, I-00144 Rome, Italy
[2] Tor Vergata Univ, Dept Biomed & Prevenz, I-00133 Rome, Italy
关键词
CAR-T in hematology; CAR-T in solid neoplasia; infectious and autoimmune disease; tumor microenvironment; tumor immunosuppression; EPSTEIN-BARR-VIRUS; CHILDREN; EXPRESSION; LEUKEMIA; EFFICACY; DISEASE; ADULTS; TUMORS; GD3; AML;
D O I
10.3390/cells14010041
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Despite the advances of CAR-T cells in certain hematological malignancies, mostly from B-cell derivations such as non-Hodgkin lymphomas, acute lymphoblastic leukemia and multiple myeloma, a significant portion of other hematological and non-hematological pathologies can benefit from this innovative treatment, as the results of clinical studies are demonstrating. The clinical application of CAR-T in the setting of acute T-lymphoid leukemia, acute myeloid leukemia, solid tumors, autoimmune diseases and infections has encountered limitations that are different from those of hematological B-cell diseases. To overcome these restrictions, strategies based on different molecular engineering platforms have been devised and will be illustrated below. The aim of this manuscript is to provide an overview of the CAR-T application in pathologies other than those currently treated, highlighting both the limits and results obtained with these settings.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Current Progress in CAR-T Cell Therapy for Hematological Malignancies
    Han, Donglei
    Xu, Zenghui
    Zhuang, Yuan
    Ye, Zhenlong
    Qian, Qijun
    JOURNAL OF CANCER, 2021, 12 (02): : 326 - 334
  • [2] Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
    Tao, Zhongfei
    Chyra, Zuzana
    Kotulova, Jana
    Celichowski, Piotr
    Mihalyova, Jana
    Charvatova, Sandra
    Hajek, Roman
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [3] The journey of CAR-T therapy in hematological malignancies
    Junru Lu
    Guan Jiang
    Molecular Cancer, 21
  • [4] The journey of CAR-T therapy in hematological malignancies
    Lu, Junru
    Jiang, Guan
    MOLECULAR CANCER, 2022, 21 (01)
  • [5] CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
    Huang, Jiawen
    Huang, Xiaobing
    Huang, Juan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [6] The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
    Zhao, Zijun
    Chen, Yu
    Francisco, Ngiambudulu M.
    Zhang, Yuanqing
    Wu, Minhao
    ACTA PHARMACEUTICA SINICA B, 2018, 8 (04) : 539 - 551
  • [7] CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
    Zhang, Xiaomin
    Zhu, Lingling
    Zhang, Hui
    Chen, Shanshan
    Xiao, Yang
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [8] CAR-T cell therapy for hematological malignancies: History, status and promise
    Wang, Chao
    Wang, Jianpeng
    Che, Shusheng
    Zhao, Hai
    HELIYON, 2023, 9 (11)
  • [9] The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
    Zijun Zhao
    Yu Chen
    Ngiambudulu M.Francisco
    Yuanqing Zhang
    Minhao Wu
    ActaPharmaceuticaSinicaB, 2018, 8 (04) : 539 - 551
  • [10] Toxicities following CAR-T therapy for hematological malignancies
    Hernani, Rafael
    Benzaquen, Ana
    Solano, Carlos
    CANCER TREATMENT REVIEWS, 2022, 111